raltegravir

Type: Keyphrase
Name: raltegravir
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Use of Third Line Antiretroviral Therapy in Latin America

by Carina Cesar, Bryan E. Shepherd, Cathy A. Jenkins, Massimo Ghidinelli, Jose Luis Castro, Valdiléa Gonçalves Veloso, Claudia P. Cortes, Denis Padgett, Brenda Crabtree-Ramirez, Eduardo Gotuzzo, Valeria Fink, Adriana Duran, Omar Sued, Catherine C. McGowan, ... [Published Plosone.org - 14 hours ago]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy

Objective: To compare bone mineral density (BMD) changes over 96 weeks in adults virologically failing standard first-line therapy, randomized to raltegravir plus lopinavir/ritonavir (RAL + LPV/r) or conventional 2-3 nucleoside/nucleotide reverse transcriptase ... [Published JAIDS - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Efficacy and Safety of Raltegravir in Racial Groups

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC Reported by Jules LevinICAAC 2014. September 5-9, 2014. Washington, DCKathleen Squires1, Linda-Gale Bekker2, Christine Katlama3, Yazdan ... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

[Department of Error] Department of Error

Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735–43—The ... [Published The Lancet - Sep 05 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Data on HIV/AIDS Discussed by Researchers at GlaxoSmithKline (Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or...

Data on HIV/AIDS Discussed by Researchers at GlaxoSmithKline (Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study)By a News Reporter-Staff News Editor ... [Published 4 Traders - Sep 05 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

The Role of Triumeq in HIV Treatment

Joel Gallant, M.D., M.P.H.The approval of Triumeq, the single-tablet coformulation of abacavir , lamivudine and the integrase inhibitor dolutegravir, is an important step forward for antiretroviral therapy. All of the previously approved single-tablet ... [Published The Body - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Raltegravir in Virologically Suppressed Overweight Women

Baker JV, Neuhaus J, Duprez D et al . Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56: 36–43.Brown TT, ... [Published General Medicine eJournal - Aug 25 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

An integrase inhibitor such as raltegravir may reduce immune activation in early therapy

Facebook Twitter Google + Email PrintA new study shows that an initial early treatment using the integrase inhibitor raltegravir (Isentress) leads to less immune activation in people with HIV than initial treatment with other drugs, including those ... [Published Project Inform - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Human medicines European public assessment report (EPAR): Isentress, raltegravir, Revision: 22, Authorised

First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

[Articles] Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. ... [Published The Lancet online - Aug 05 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Charcot Project: INSPIRE Trial fully recruited

The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ... [Published Multiple Sclerosis Research - Jul 30 2014]
First reported Jun 05 2014 - Updated Jun 06 2014 - 4 reports

Merck begins patient enrollment in Phase III trial of HIV-drug Isentress

Merck has started patient enrollment in its global Phase III clinical trial 'ONCEMRK', which is evaluating a once-daily investigational formulation of Isentress (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve ... [Published PBR - News - Jun 06 2014]

Quotes

Can we reduce human endogenous retroviruses or HERVs with a treatment? #MSBlog #MSResearch "Just arrived back from Boston; exhausted physically, mentally and no doubt more to come with jet-lag. One of the highlights for me at ECTRIMS was the interest in human endogenous retroviruses (HERV) and MS. The following is some interesting preliminary results from the clinical study of a monoclonal antibody targeting the envelope protein of a HERV associated with MS. What it shows is that this antibody decreases expression of this virus and the protein. Hopefully these effects will be associated with a reduction in MS disease-activity. This is what we are trying to achieve in our INSPIRE study using a drug, raltegravir, that targets HERV biology. We will also be doing biomarker studies to see if we down-regulate peripheral HERV expression. Please remember HERV transactivation, or expression in MS, may simply be an epiphenomenon, of inflammation. This is why it is so important to  have to see if reduced expression of HERVs is associated with a therapeutic effect."
...In June 2014, PrEP was again cited by CDC as an important part of HIV prevention efforts. Later that month, New York Governor Cuomo chose "providing access to Pre-Exposure Prophylaxis (PrEP) for high-risk persons to keep them HIV negative" as one of the three cornerstones of his plan to end the HIV epidemic in New York state...
"The correlation between gSCA and levels of infectious virus suggests that HIV-1 RNA in the plasma may originate from stochastic reactivation of latently infected cells, and that changes in levels of HIV-1 RNA in plasma following an intervention may be reflective of changes in the size of the latent reservoir. Future studies should seek to further elucidate the relationship between persistent plasma viremia and the infectious virus reservoir."
"The high virologic response and low rate of discontinuation with 3D + ribavirin in genotype 1 HCV/HIV-1 coinfected patients are consistent with HCV genotype 1-monoinfected patients, despite multiple unfavorable predictors of response" the researchers concluded

More Content

All (49) | News (30) | Reports (0) | Blogs (19) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Use of Third Line Antiretroviral Therapy in Lat... [Published Plosone.org - 14 hours ago]
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - 18 hours ago]
Cipla enters into a licensing agreement with Gi... [Published India Infoline - 22 hours ago]
Health Insurance Companies Are the Biggest Impe... [Published The Body - Sep 12 2014]
Bone Mineral Density Over 96 Weeks in Adults Fa... [Published JAIDS - Sep 11 2014]
Improved Single Copy Assays for Quantification ... [Published National AIDS Treatment Advocacy Project - Sep 10 2014]
Efficacy and Safety of Raltegravir in Racial Gr... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]
ICAAC 2014: AbbVie 3D Regimen Works Well for Pe... [Published HIV and Hepatitis.com - Sep 08 2014]
[Department of Error] Department of Error [Published The Lancet - Sep 05 2014]
Data on HIV/AIDS Discussed by Researchers at Gl... [Published 4 Traders - Sep 05 2014]
Advances in the works for STDs [Published Examiner.com - Aug 29 2014]
The Role of Triumeq in HIV Treatment [Published The Body - Aug 26 2014]
FDA Approves New Single-Tablet HIV Regimen, Tri... [Published POZ.com - Aug 25 2014]
Raltegravir in Virologically Suppressed Overwei... [Published General Medicine eJournal - Aug 25 2014]
Another full-regimen HIV pill enters the market... [Published Project Inform - Aug 22 2014]
Enanta Pharmaceuticals Updates on 3rd Quarter F... [Published Pharmacy Choice - Aug 18 2014]
Could HIV drugs help treat multiple sclerosis? [Published Nursing Times - Aug 18 2014]
Peripheral Neuropathy in Primary HIV Infection [Published General Medicine eJournal - Aug 18 2014]
Nonoccupational Postexposure Prophylaxis for HI... [Published General Medicine eJournal - Aug 18 2014]
Cipla consolidated net dips by 39% in Q1 [Published PharmaBiz - Aug 16 2014]
HIV May Help Prevent Multiple Sclerosis [Published Sudan Vision Daily - Aug 13 2014]
Researchers at University of Minnesota Target H... [Published 4 Traders - Aug 13 2014]
Researchers Find Hepatitis C Cures Effective fo... [Published BlackAIDS.org - Aug 12 2014]
An integrase inhibitor such as raltegravir may ... [Published Project Inform - Aug 12 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
HIV/AIDS: What New Treatment Options Are Availa... [Published BlackDoctor.org - Aug 08 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jul 15 2014]
Merck seeks to settle patent row with Glenmark [Published Times of India - Jul 12 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - 18 hours ago]
Can we reduce human endogenous retroviruses or HERVs with a treatment? #MSBlog #MSResearch "Just arrived back from Boston; exhausted physically, mentally and no doubt more to come with jet-lag. One of the highlights for me at ECTRIMS was the interest ...
[Department of Error] Department of Error [Published The Lancet - Sep 05 2014]
Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735–43—The ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. ...
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.